Loading clinical trials...
Loading clinical trials...
AMP-011 is a Phase 1 study designed to extend the understanding of the toxicity and pharmacology of imexon by investigating a schedule of daily treatment for 5 days every three weeks. The objective of...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
AmpliMed Corporation
NCT07174336 · Breast Neoplasms, Neoplasm Metastasis
NCT07213804 · Ovarian Neoplasms, Fallopian Tube Neoplasms, and more
NCT07046923 · Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, and more
NCT05614739 · Urinary Bladder Neoplasms, Neoplasm Metastasis, and more
NCT06912087 · Head and Neck Neoplasms, Carcinoma, Squamous Cell, and more
US Oncology Indiana
Indianapolis, Indiana
US Oncology Albany, New York Oncology
Albany, New York
Investigational Site 014
Temple, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions